Tranzactioneaza Sage Therapeutics Inc (US.SAGE) - 9.235 USD (%) Tranzactioneaza
Indici
Descriere companie
SAGE Therapeutics, Inc. (https://www.sagerx.com/) is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.